- 期刊
- OpenAccess
Adipokines, C-Reactive Protein and Lipid Profile Levels in Hypertensive Type 2 Diabetic Portuguese Patients
並列摘要
Type 2 diabetes mellitus (T2DM) and hypertension are known to be associated. We aimed to study how hypertension may influence the levels of adipogenesis, inflammation and lipid metabolism in patients with T2DM. We studied 57 normotensive and 23 hypertensive patients with T2DM. The circulating levels of some adipokines - adiponectin, leptin and chemerin-, C-reactive protein (CRP) and the lipid profile were evaluated. The hypertensive group (HG) of patients with T2DM presented significantly higher weight and BMI values (28.6±2.8 vs 26.4±4.2 kg/m^2) than the normotensive group of patients (NG) with T2DM. The HG, compared to the NG, presented significantly higher levels of chemerin (185 [163-218] vs 166 [125-188] ng/mL), CRP (2.40 [1.87-5.12] vs 1.78 [0.64-3.71] mg/L) and triglycerides (139 [99-192] vs 99 [76-138] mg/dL), a trend towards lower levels of adiponectin, as well as higher values of total cholesterol and increased levels of leptin more evident in males. When statistical adjustment for the confounding factor BMI was performed, the significances observed were lost. In summary, hypertensive patients with T2DM presented raised BMI with altered adipokine secretion, namely raised chemerin levels, abnormal lipid profile and enhanced CRP concentrations, which probably underlie the association of hypertension with obesity.
延伸閱讀
- 莊佳龍（2014）。Retrospective Study of Dipeptidyl Peptidase-IV Inhibitor of Anti-diabetic Agents〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-2101201410043200
- Saltevo, J., Vanhala, M., Kautiainen, H., Kumpusalo, E., & Laakso, M. (2007). Association of C-Reactive Protein, Interleukin-1 Receptor Antagonist and Adiponectin with the Metabolic Syndrome. Mediators of Inflammation, 2007(), 413-420. https://doi.org/10.1155/2007/93573
- Otamere, H. O., Aloamaka, C. P., Okokhere, P. O., & Adisa, W. A. (2011). Lipid Profile in Diabetes Mellitus; What Impact Has Age and Duration. British Journal of Pharmacology and Toxicology, 2(3), 135-137. https://www.airitilibrary.com/Article/Detail?DocID=20442467-201108-201507070013-201507070013-135-137
- 蕭淑華、歐弘毅、吳達仁（2007）。Clinical Evidence of GLP-1 Receptor Agonists and DPP Ⅵ Inhibitors in the Treatment of Type 2 Diabetes。內科學誌，18(4)，189-194。https://doi.org/10.6314/JIMT.2007.18(4).03
- Mesallamy, H. E., Suwailem, S., & Hamdy, N. (2007). Evaluation of C-Reactive Protein, Endothelin-1, Adhesion Molecule(s), and Lipids as Inflammatory Markers in Type 2 Diabetes Mellitus Patients. Mediators of Inflammation, 2007(), 333-339. https://doi.org/10.1155/2007/73635